Navigation Links
Biodel Announces $18.5 Million Private Placement
Date:6/22/2012

DANBURY, Conn., June 22, 2012 /PRNewswire/ -- Biodel Inc. (NASDAQ:  BIOD) today announced that it has entered into a definitive securities purchase agreement with a group of institutional investors, including both existing and new investors, for the private placement of approximately 7.9 million shares of its capital stock and warrants to purchase approximately 2.7 million shares of its common stock.  A portion of the shares to be issued will be shares of Biodel's common stock and a portion will be shares of its Series B Preferred Stock.  For each share being purchased, investors will receive a warrant to purchase 0.35 of a share of common stock. 

For each unit consisting of a share and warrant, the investors have agreed to pay a negotiated price of $2.355, resulting in gross proceeds to Biodel, before deducting placement agents' fees and estimated offering expenses of approximately $18.5 million.  The private placement is expected to close on or about June 27, 2012, subject to customary closing conditions.

The Series B Convertible Preferred Stock is non-voting.  Each share of Series B Convertible Preferred Stock is convertible into one share of Biodel's common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 9.98% of the total number of Biodel shares of common stock outstanding following such conversion.  The per share exercise price of the warrants is $2.66.  The warrants will be exercisable beginning on the original date of issuance and will expire on the date that is five years after the original issue date.

William Blair & Company, L.L.C. acted as Sole Lead Placement Agent and JMP Securities LLC acted as Co-Agent for the private placement.

The securities offered and to be sold by Biodel in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act
'/>"/>

SOURCE Biodel Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
3. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... June 18, 2013  Actavis, Inc. (NYSE: ACT ... with the U.S. Securities and Exchange Commission (SEC) a registration ... of Warner Chilcott plc (NASDAQ: WCRX ... Warner Chilcott (the "Form S-4"). As ... Chilcott have entered into a definitive agreement pursuant to ...
(Date:6/18/2013)... CITY, N.Y. , June 18, 2013 /PRNewswire/ ... that it has entered into an exclusive 25-year ... Mid-Atlantic regions with eWellness Corporation ("EWC") for its ... "An easy to use physical therapy program is ... diabetes and cardiovascular disease," said Chris Amandola ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
... , - Research Collaboration ... Jubilant Organosys Ltd, headquartered ... subsidiary,Jubilant Biosys Ltd, has signed a research,collaboration agreement ... into the international pharmaceutical company,s pre-clinical,pipeline. Under the ...
... EPSScentral LLC today announced its readiness to assist ... the face of WHO,s phase 5 classification of the ... 5 "... is a strong signal that a pandemic ... measures is short." (Logo: http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO ...
Cached Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4EPSScentral Responds to Pandemic Alert 2
(Date:6/19/2013)... Scott Tischler of Tischler Brothers Fitness unveils how to kick ... very first thing that should be done every morning is ... The body is dehydrated when it first wakes up and ... and will also kick start the metabolism first thing in ... the water to body temperature before it can be digested ...
(Date:6/19/2013)... According to Vanessa Grigoriadis, a contributing ... are creating new designer drugs featuring psychoactive effects by ... documents and patented formulas. She reported her findings to ... on June 4. , “Some of these drugs could ... on humans. Maybe some of them are tested on ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Sudden cardiac arrest can strike anyone, even a child, at ... minutes after cardiac arrest, but the average emergency medical service ... is highly probable if an automated external defibrillator or ... to this dire reality, US Representative Lois Capps (CA-24) has ... which would provide support for AED and CPR training programs ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Transvaginal mesh lawsuits ... matter. A May 31 order addressed how to handle evidence ... preserve and test samples and device components removed from patients. ... informational website , complete with news about the device and ... are to obtain the samples from the medical facilities that ...
Breaking Medicine News(10 mins):Health News:Dangerous Designer Drugs Dodge Legal System 2Health News:Dangerous Designer Drugs Dodge Legal System 3Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
... 11 MedImmune, the,global biologics unit of AstraZeneca, ... Holdings, Inc., announced today that they have entered,into ... commercialize,SBI Biotech,s anti-ILT7 protein for the potential treatment ... MedImmune has,global rights to any resulting product candidates ...
... back,to school, parents gain flexibility in what their ... Department of Agriculture (USDA),announced parents or legal guardians ... cow,s milk for children receiving National School Lunch ... growing diversity of,participants in the School Nutrition Programs ...
... Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... pharmaceutical company in the People,s Republic,of China, today ... a,total value of approximately $12 million over the ... the 43rd Annual New Drugs Conference (the,"Conference") sponsored ...
... MIT study suggests , , THURSDAY, Sept. 11 (HealthDay News) -- ... your eyes. , A team of neuroscientists publishing ... they have tricked the brain into confusing one object the ... humans to learn to recognize objects. , People never really ...
... waiting room time more enjoyable and informative for patients, ... and helping doctors become more profitable in the process. ... is Ear, Nose & Throat Associates of South Florida ... month in Chicago at AOA-26 and OTO EXPO and ...
... NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global ... will web cast the,presentation by Harvey Kamil, President and ... Ideas Conference in New York on Wednesday,September 17, 2008., ... live on NBTY,s web site, (http://www.nbty.com ) on Wednesday, ...
Cached Medicine News:Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2Health News:Parents Can Now Ask Schools to Serve Soymilk 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 2Health News:Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million 3Health News:Time Teaches Brain to Recognize Objects 2Health News:Mediplay Makes Marketing More Profitable For Physicians 2Health News:Mediplay Makes Marketing More Profitable For Physicians 3Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
HME w/bacterial viral filter w/CO2...
Indications For Usage: ,Infant (recommended tidal volume 20-70ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended ...
Medicine Products: